| 商品名称 | CaniLeish |
|---|---|
| 适用类别 | Veterinary |
| 治疗领域 | |
| 通用名/非专利名称 | Leishmania infantum excreted secreted proteins |
| 活性成分 | Leishmania infantum excreted secreted proteins |
| 产品号 | EMEA/V/C/002232 |
| 患者安全信息 | No |
| 许可状态 | Withdrawn |
| ATC编码 | QI07AO |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2011/03/14 |
| 上市许可开发者/申请人/持有人 | Virbac S.A. |
| 人用药物治疗学分组 | |
| 兽用药物治疗学分组 | Immunologicals |
| 欧盟委员会决定日期 | 2016/01/07 |
| 修订号 | 2 |
| 治疗适应症 | For the active immunisation of Leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with Leishmania infantum. The efficacy of the vaccine has been demonstrated in dogs submitted to multiple natural parasite exposure in zones with high infection pressure. Onset of immunity: 4 weeks after the primary vaccination course. Duration of immunity: 1 year after the last re-vaccination. |
| 适用物种 | Dogs |
| 兽用药物ATC编码 | QI07AO |
| 首次发布日期 | 2016/01/07 |
| 最后更新日期 | 2023/10/24 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/canileish-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/veterinary/EPAR/canileish |